Applied Filters
WHO plans to vaccinate Africa with Moderna COVID vaccine hit stumbling block
Just 12 African countries have hit WHO’s 10% vaccination target as supply chain issues worsen.
Intel backs Mylan's anti-Fintiv SCOTUS stance
Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.
Bausch settles $300m antitrust case over diabetes drug price hikes
Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Australia backs COVID-19 vaccine waiver
Australia will waive IP protections for COVID-19 vaccines to enable more cost-effective copycat versions to be manufactured in developing countries, in the wake of mounting pressure from human rights groups and governments worldwide.
Teva drops lawsuit with Amicus over Creates Act dispute
Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Mylan, Edwards back NHK-Fintiv challenge
Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.
South Korea asks US for access to vaccine IP
South Korean officials have urged the US government to help Korean companies gain access to IP related to producing COVID-19 jabs.
Fed Circ written description ruling overturns $1.2 billion award
Kite Pharma has successfully persuaded the US Court of Appeals for the Federal Circuit to reverse a $1.2 billion win for the Bristol-Meyers Squibb owned Juno Therapeutics over a cancer treatment patent.
Regeneron asks court to dismiss COVID-19 tech patent suit
Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.
